Ecolab Inc. (ECL) Stock Analysis and Metrics

Ecolab

NYSE: ECL

$268.73 ▲ +5.58 (+2.12%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap76.02 Bn

P/E30.01

P/S4.73

Div. Yield0.01

ROIC (Qtr)0.01

Total Debt (Qtr)8.24 Bn

Revenue Growth (1y) (Qtr)4.76

Add ratio to table…

About

Ecolab is a global leader in water hygiene and infection prevention solutions and services that protect people and the resources vital to life. The company generates $16 billion in annual sales employs approximately 48,000 associates and serves customers in more than 170 countries across 40 industries. It helps protect one third of the world’s food production and a quarter of the power generated while providing solutions for food healthcare data centers microelectronics life sciences and hospitality.

Ecolab generates revenue primarily from the sale of products and equipment recognized at the point when contractual obligations are satisfied. It also earns service revenue particularly from its pest elimination operations which is recognized over time as services are delivered. The company’s offerings include water treatment programs cleaning and sanitizing solutions infection prevention products and pest management services.

The company operates through the following segments: Global Water Global Institutional & Specialty Global Pest Elimination and Global Life Sciences.

• Global Water: This segment provides water treatment and process applications along with cleaning and sanitizing solutions primarily to large industrial customers in manufacturing food and beverage processing transportation chemical primary metals and mining power generation global refining petrochemical and pulp and paper industries. It offers products for cooling water ultra pure water wastewater boiler water and process water applications and specialty programs for the petroleum and fuels industry including refining process applications fuels and feedstocks additives.

• Global Institutional & Specialty: This segment delivers specialized cleaning and sanitizing products infection prevention solutions food safety equipment and janitorial services to hospitality healthcare foodservice lodging government education and retail customers. It also supplies tailored cleaning and sanitation programs to quick service restaurant chains and food retailers and provides a digital food safety platform for kitchen procedure automation and compliance.

• Global Pest Elimination: This segment provides services to detect prevent and eliminate pests such as rodents and insects in full service and quick service restaurants food and beverage processors hotels grocery operations and education life sciences and healthcare facilities. Revenue is derived mainly from service contracts recognized over time as the pest management work is performed.

• Global Life Sciences: This segment offers end to end cleaning and contamination control solutions to pharmaceutical and personal care manufacturers including detergents cleaners sanitizers disinfectants surface wipes cleaning systems electronic dispensers and chemical injectors. It also provides premium fluid treatment and purification solutions under the Purolite brand and decontamination systems using hydrogen peroxide vapor under the Bioquell brand serving customers in pharma animal health blood purification biologics cosmetics and medical devices.

Ecolab holds a leading position in the global water hygiene and infection prevention markets competing against a few large multinational corporations and numerous smaller regional players. Its competitive advantages stem from demonstrated value technical expertise innovation digital technology chemical formulations global customer support detection equipment monitoring capabilities and dosing and metering equipment. These strengths enable the company to help customers optimize water and energy use improve productivity advance food safety and achieve sustainability goals while lowering total cost of operations.

Ecolab serves a diverse customer base that includes manufacturers food and beverage processors hospitals hotels quick service restaurant chains grocery stores pharmaceutical companies data centers microelectronics facilities and life sciences businesses. The company’s presence spans more than 170 countries and 40 industries with no single customer accounting for ten percent or more of its total revenue.

Investment Thesis

▲ Bull case

Ecolab's growth engines are collectively delivering 12% organic growth at high margins, with Global High Tech and Digital exceeding 20% growth and Life Sciences posting 11% growth driven by bioprocessing where sales more than doubled, indicating that these segments are becoming the primary drivers of future performance and are largely insulated from commodity cost inflation and energy price volatility, which positions the company to sustain margin expansion and earnings growth even in a challenging macro environment.
The pending CoolIT acquisition, while causing a short-term EPS dilution of $0.20 per quarter in the second half of 2026, is expected to accelerate growth significantly, with first-quarter sales already close to triple-digit range, and when combined with OVIVO and the existing Global High Tech business, will form a $1.5 billion unit growing 20%-25%+ at high margin, adding a couple of points of high-margin organic sales growth to company-wide performance and positioning Ecolab as a leader in direct-to-chip liquid cooling and ultra-pure water solutions for AI-driven data centers and semiconductor manufacturing, a market with secular tailwinds from the AI infrastructure buildout.
Life Sciences is projected to maintain double-digit growth and expand operating income margin toward the 30% target over the next few years, supported by new capacity coming online in the second half of 2026 and continued strong demand in bioprocessing, which grew north of 100% in the quarter, indicating that the business is transitioning from investment phase to profit generation phase with significant operating leverage potential as scale increases.
The implementation of energy surcharges affecting 100% of customers and businesses, with execution expected to complete by late Q2 or early Q3, is already allowing Ecolab to offset the impact of higher commodity costs, with management expecting to fully offset the dollar impact from higher commodity costs as they exit Q2, and ex-OVIVO gross margin anticipated to rise 70-80 basis points in the second half, demonstrating effective pricing power and cost pass-through ability that protects margins despite inflationary pressures.
Pest Intelligence rollout, with approximately 700,000 smart devices deployed and targeting 1 million by year-end, is creating a structural advantage in customer retention and service efficiency, transforming previously non-value-added trap-checking time into sales opportunities, which will drive margin improvement and recurring revenue growth in the Pest Elimination segment over the next three to four years as full penetration is achieved.

Ecolab's growth engines are collectively delivering 12% organic growth at high margins, with Global High Tech and Digital exceeding 20% growth and Life Sciences posting 11% growth driven by bioprocessing where sales more than doubled, indicating that these segments are becoming the primary drivers of future performance and are largely insulated from commodity cost inflation and energy price volatility, which positions the company to sustain margin expansion and earnings growth even in a challenging macro environment.
The pending CoolIT acquisition, while causing a short-term EPS dilution of $0.20 per quarter in the second half of 2026, is expected to accelerate growth significantly, with first-quarter sales already close to triple-digit range, and when combined with OVIVO and the existing Global High Tech business, will form a $1.5 billion unit growing 20%-25%+ at high margin, adding a couple of points of high-margin organic sales growth to company-wide performance and positioning Ecolab as a leader in direct-to-chip liquid cooling and ultra-pure water solutions for AI-driven data centers and semiconductor manufacturing, a market with secular tailwinds from the AI infrastructure buildout.
Life Sciences is projected to maintain double-digit growth and expand operating income margin toward the 30% target over the next few years, supported by new capacity coming online in the second half of 2026 and continued strong demand in bioprocessing, which grew north of 100% in the quarter, indicating that the business is transitioning from investment phase to profit generation phase with significant operating leverage potential as scale increases.
The implementation of energy surcharges affecting 100% of customers and businesses, with execution expected to complete by late Q2 or early Q3, is already allowing Ecolab to offset the impact of higher commodity costs, with management expecting to fully offset the dollar impact from higher commodity costs as they exit Q2, and ex-OVIVO gross margin anticipated to rise 70-80 basis points in the second half, demonstrating effective pricing power and cost pass-through ability that protects margins despite inflationary pressures.
Pest Intelligence rollout, with approximately 700,000 smart devices deployed and targeting 1 million by year-end, is creating a structural advantage in customer retention and service efficiency, transforming previously non-value-added trap-checking time into sales opportunities, which will drive margin improvement and recurring revenue growth in the Pest Elimination segment over the next three to four years as full penetration is achieved.

▼ Bear case

Despite strong performance in growth segments, Ecolab's core businesses continue to face structural headwinds, as evidenced by the stabilization of Paper and Heavy Water segments only recently occurring after prolonged underperformance, and with management admitting these areas are not a focus of strategic investment, indicating that a meaningful portion of the portfolio remains in low-growth, low-margin businesses that could continue to dilute overall returns if they fail to transition to positive contributors.
The company's reliance on pricing actions to offset commodity cost inflation, including the implementation of energy surcharges affecting 100% of customers, carries the risk of customer pushback or volume degradation over time, especially if macroeconomic conditions worsen, and while management claims they have successfully used this approach before, the current environment features sustained high single-digit commodity cost increases expected to remain elevated through year-end, which could pressure volume growth if customers resist further price hikes.
The pending CoolIT acquisition, while strategically compelling, introduces integration and execution risks, as acknowledged by management's admission that the technology changeover could be rapid and that cold plates and related infrastructure are not a core competency of Ecolab, raising concerns about the company's ability to effectively scale and support a high-growth, high-technology business that requires specialized R&D and manufacturing capabilities beyond its traditional water and chemistry expertise.
Life Sciences' projected expansion toward a 30% operating income margin target over the next few years is contingent on continued investment in capacity and innovation, and with management acknowledging that they will be in the mid-20s margin range in the short to mid-term as they build new capacity, there is uncertainty about the timing and magnitude of operating leverage, especially if demand growth does not sustain its current pace or if new capacity is underutilized.
Pest Intelligence rollout, while progressing with 700,000 smart devices deployed, targets full penetration in three to four years, meaning the margin benefits from improved service efficiency and customer retention are still years away, and until then, the segment remains dependent on traditional pest control methods, which could limit near-term margin expansion despite the digital initiative's long-term promise.

Despite strong performance in growth segments, Ecolab's core businesses continue to face structural headwinds, as evidenced by the stabilization of Paper and Heavy Water segments only recently occurring after prolonged underperformance, and with management admitting these areas are not a focus of strategic investment, indicating that a meaningful portion of the portfolio remains in low-growth, low-margin businesses that could continue to dilute overall returns if they fail to transition to positive contributors.
The company's reliance on pricing actions to offset commodity cost inflation, including the implementation of energy surcharges affecting 100% of customers, carries the risk of customer pushback or volume degradation over time, especially if macroeconomic conditions worsen, and while management claims they have successfully used this approach before, the current environment features sustained high single-digit commodity cost increases expected to remain elevated through year-end, which could pressure volume growth if customers resist further price hikes.
The pending CoolIT acquisition, while strategically compelling, introduces integration and execution risks, as acknowledged by management's admission that the technology changeover could be rapid and that cold plates and related infrastructure are not a core competency of Ecolab, raising concerns about the company's ability to effectively scale and support a high-growth, high-technology business that requires specialized R&D and manufacturing capabilities beyond its traditional water and chemistry expertise.
Life Sciences' projected expansion toward a 30% operating income margin target over the next few years is contingent on continued investment in capacity and innovation, and with management acknowledging that they will be in the mid-20s margin range in the short to mid-term as they build new capacity, there is uncertainty about the timing and magnitude of operating leverage, especially if demand growth does not sustain its current pace or if new capacity is underutilized.
Pest Intelligence rollout, while progressing with 700,000 smart devices deployed, targets full penetration in three to four years, meaning the margin benefits from improved service efficiency and customer retention are still years away, and until then, the segment remains dependent on traditional pest control methods, which could limit near-term margin expansion despite the digital initiative's long-term promise.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Specialty Chemicals

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	LIN	Linde Plc	237.95 Bn	33.52	6.87	24.68 Bn
2	SHW	Sherwin Williams Co	78.17 Bn	30.07	3.27	11.70 Bn
3	ECL	Ecolab Inc.	76.02 Bn	30.01	4.73	8.24 Bn
4	APD	Air Products & Chemicals, Inc.	66.38 Bn	47.14	5.33	17.40 Bn
5	PPG	Ppg Industries Inc	26.02 Bn	3,717.41	1.61	7.83 Bn
6	LYB	LyondellBasell Industries N.V.	22.51 Bn	-28.53	0.76	11.45 Bn
7	SQM	Chemical & Mining Co Of Chile Inc	19.70 Bn	21.77	3.72	4.79 Bn
8	IFF	International Flavors & Fragrances Inc	19.51 Bn	-102.16	1.81	5.82 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password